ctx-009
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 30, 2022 (NCT05506943)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06548412 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | University of Texas at Houston |
| NCT05513742 | Phase 2 | Dec 8, 2022 | Compass Therapeutics |
| NCT05506943 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2022 | Compass Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Compass Therapeutics | For profit | 2 | 2 | 2 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1